JP4928256B2 - 肥満を治療するための、フィブラート系薬剤及びオルリスタットの使用 - Google Patents
肥満を治療するための、フィブラート系薬剤及びオルリスタットの使用 Download PDFInfo
- Publication number
- JP4928256B2 JP4928256B2 JP2006505148A JP2006505148A JP4928256B2 JP 4928256 B2 JP4928256 B2 JP 4928256B2 JP 2006505148 A JP2006505148 A JP 2006505148A JP 2006505148 A JP2006505148 A JP 2006505148A JP 4928256 B2 JP4928256 B2 JP 4928256B2
- Authority
- JP
- Japan
- Prior art keywords
- orlistat
- fibrate
- fibrates
- fenofibrate
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dental Preparations (AREA)
Description
<フィブラート系薬剤とオルリスタットの併用投与が体重に及ぼす影響>
この研究は、フィブラート系薬剤とオルリスタットの併用が体重に及ぼす影響を調べるために設計したものである。
動物:
体重約20gのマウスをCERJから入手した。マウスはそれぞれ別のケージに入れ、温度、湿度及び光を調節した部屋(21〜23℃、明暗サイクル12時間)に静置した。マウスには研究用標準飼料又は高脂肪飼料を与え、水を自由に飲ませた。順応させた後、体重に応じてマウスを20匹ずつの群に無作為に分けた。
*1群:
高脂肪飼料を与えたマウス
*2群:
フェノフィブラート25mg/kgを高脂肪飼料に混合して経口投与したマウス
*3群:
オルリスタット2.5mg/kgを高脂肪飼料に混合して経口投与したマウス
*4群:
フェノフィブラート25mg/kg及びオルリスタット2.5mg/kgを高脂肪飼料に混合して経口投与したマウス
*5群:
標準飼料を与えたマウス
Claims (8)
- 肥満治療用薬剤の製造における、フィブラート系薬剤、オルリスタット及び医薬品に許容される担体の使用であって、
フィブラート系薬剤は、フェノフィブラートである
ことを特徴とする使用。 - フィブラート系薬剤とオルリスタットを同時に又は順次投与する
ことを特徴とする請求項1に記載の使用。 - フィブラート系薬剤の有効量は一日当たり10〜3000mgである
ことを特徴とする請求項1又は2に記載の使用。 - オルリスタットの有効量は一日当たり50〜1440mgである
ことを特徴とする請求項1〜3のいずれか1項に記載の使用。 - フィブラート系薬剤、オルリスタット及び医薬品に許容される担体を含む医薬組成物であって、
フィブラート系薬剤は、フェノフィブラートである
ことを特徴とする肥満治療用医薬組成物。 - フィブラート系薬剤を10〜1000mg含む
ことを特徴とする請求項5に記載の肥満治療用医薬組成物。 - オルリスタットを50〜720mg含む
ことを特徴とする請求項5又は6に記載の肥満治療用医薬組成物。 - オルリスタットを120〜360mg含む
ことを特徴とする請求項5〜7のいずれか1項に記載の肥満治療用医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03290625A EP1457206A1 (en) | 2003-03-13 | 2003-03-13 | Combined use of a fibrate and orlistat for the treatment of obesity |
EP03290625.7 | 2003-03-13 | ||
PCT/EP2004/004010 WO2004080450A2 (en) | 2003-03-13 | 2004-03-12 | Combined use of a fibrate and orlistat for the treatment of obesity |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006520365A JP2006520365A (ja) | 2006-09-07 |
JP4928256B2 true JP4928256B2 (ja) | 2012-05-09 |
Family
ID=32749013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006505148A Expired - Fee Related JP4928256B2 (ja) | 2003-03-13 | 2004-03-12 | 肥満を治療するための、フィブラート系薬剤及びオルリスタットの使用 |
Country Status (19)
Country | Link |
---|---|
US (1) | US20070078179A1 (ja) |
EP (2) | EP1457206A1 (ja) |
JP (1) | JP4928256B2 (ja) |
CN (1) | CN100562313C (ja) |
AT (1) | ATE384520T1 (ja) |
AU (1) | AU2004218938B2 (ja) |
BR (1) | BRPI0408322A (ja) |
CA (1) | CA2518205C (ja) |
DE (1) | DE602004011486T2 (ja) |
DK (1) | DK1601352T3 (ja) |
EA (1) | EA009127B1 (ja) |
ES (1) | ES2300750T3 (ja) |
HK (1) | HK1083767A1 (ja) |
IL (1) | IL170519A (ja) |
MX (1) | MXPA05009718A (ja) |
NO (1) | NO20054700L (ja) |
PT (1) | PT1601352E (ja) |
WO (1) | WO2004080450A2 (ja) |
ZA (1) | ZA200507227B (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2617688C (en) * | 2007-02-22 | 2015-08-18 | Alpex Pharma S.A. | Solid dosage formulations containing weight-loss drugs |
EP2190303A1 (en) * | 2007-09-12 | 2010-06-02 | Københavns Universitet | Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety |
US20120053172A1 (en) | 2009-02-12 | 2012-03-01 | Cooperatieve Mirzorg U.A. | Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders |
EP2558105B1 (en) | 2010-04-12 | 2019-11-20 | Reata Pharmaceuticals, Inc. | Bardoxolone methyl for the treatment of obesity |
MX336980B (es) * | 2010-12-21 | 2016-02-09 | Senosiain S A De C V Lab | Combinacion y composicion para el tratamiento de obesidad. |
WO2014094956A1 (de) * | 2012-12-21 | 2014-06-26 | Merck Patent Gmbh | Magnesiumhydroxidcarbonat als träger in pharmazeutischen zubereitungen mit verbesserter wirkstofffreisetzung |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001139491A (ja) * | 1999-11-10 | 2001-05-22 | Pfizer Prod Inc | apoB分泌/MTP阻害剤及び抗肥満剤の使用 |
WO2003099836A1 (en) * | 2002-05-20 | 2003-12-04 | Bristol-Myers Squibb Company | C-aryl glucoside sglt2 inhibitors and method |
JP2006508995A (ja) * | 2002-11-28 | 2006-03-16 | フルニエ ラボラトリーズ アイルランド リミテッド | 血清トリグリセリド値を低下させるためのPPARαアゴニスト及びメトホルミンの使用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
CA1328881C (en) * | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
TW438784B (en) * | 1997-08-29 | 2001-06-07 | Ssp Co Ltd | Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same |
PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
WO2001060807A1 (en) * | 2000-02-18 | 2001-08-23 | Merck & Co. Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
-
2003
- 2003-03-13 EP EP03290625A patent/EP1457206A1/en not_active Withdrawn
-
2004
- 2004-03-12 WO PCT/EP2004/004010 patent/WO2004080450A2/en active IP Right Grant
- 2004-03-12 JP JP2006505148A patent/JP4928256B2/ja not_active Expired - Fee Related
- 2004-03-12 BR BRPI0408322-9A patent/BRPI0408322A/pt not_active IP Right Cessation
- 2004-03-12 AT AT04720007T patent/ATE384520T1/de active
- 2004-03-12 ES ES04720007T patent/ES2300750T3/es not_active Expired - Lifetime
- 2004-03-12 US US10/548,909 patent/US20070078179A1/en not_active Abandoned
- 2004-03-12 EA EA200501259A patent/EA009127B1/ru not_active IP Right Cessation
- 2004-03-12 PT PT04720007T patent/PT1601352E/pt unknown
- 2004-03-12 ZA ZA200507227A patent/ZA200507227B/xx unknown
- 2004-03-12 CN CNB2004800068916A patent/CN100562313C/zh not_active Expired - Fee Related
- 2004-03-12 DE DE602004011486T patent/DE602004011486T2/de not_active Expired - Lifetime
- 2004-03-12 AU AU2004218938A patent/AU2004218938B2/en not_active Ceased
- 2004-03-12 DK DK04720007T patent/DK1601352T3/da active
- 2004-03-12 MX MXPA05009718A patent/MXPA05009718A/es active IP Right Grant
- 2004-03-12 EP EP04720007A patent/EP1601352B1/en not_active Expired - Lifetime
- 2004-03-12 CA CA2518205A patent/CA2518205C/en not_active Expired - Fee Related
-
2005
- 2005-08-25 IL IL170519A patent/IL170519A/en not_active IP Right Cessation
- 2005-10-12 NO NO20054700A patent/NO20054700L/no not_active Application Discontinuation
-
2006
- 2006-05-29 HK HK06106181A patent/HK1083767A1/xx not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001139491A (ja) * | 1999-11-10 | 2001-05-22 | Pfizer Prod Inc | apoB分泌/MTP阻害剤及び抗肥満剤の使用 |
WO2003099836A1 (en) * | 2002-05-20 | 2003-12-04 | Bristol-Myers Squibb Company | C-aryl glucoside sglt2 inhibitors and method |
JP2006508995A (ja) * | 2002-11-28 | 2006-03-16 | フルニエ ラボラトリーズ アイルランド リミテッド | 血清トリグリセリド値を低下させるためのPPARαアゴニスト及びメトホルミンの使用 |
Also Published As
Publication number | Publication date |
---|---|
DE602004011486T2 (de) | 2009-01-15 |
WO2004080450A2 (en) | 2004-09-23 |
CA2518205A1 (en) | 2004-09-23 |
CA2518205C (en) | 2012-05-08 |
DE602004011486D1 (de) | 2008-03-13 |
CN1826108A (zh) | 2006-08-30 |
JP2006520365A (ja) | 2006-09-07 |
DK1601352T3 (da) | 2008-05-13 |
US20070078179A1 (en) | 2007-04-05 |
EP1601352A2 (en) | 2005-12-07 |
ES2300750T3 (es) | 2008-06-16 |
EA200501259A1 (ru) | 2006-02-24 |
MXPA05009718A (es) | 2005-10-18 |
PT1601352E (pt) | 2008-04-07 |
CN100562313C (zh) | 2009-11-25 |
AU2004218938B2 (en) | 2009-04-09 |
ATE384520T1 (de) | 2008-02-15 |
BRPI0408322A (pt) | 2006-03-14 |
EA009127B1 (ru) | 2007-10-26 |
NO20054700L (no) | 2005-10-12 |
ZA200507227B (en) | 2006-11-29 |
HK1083767A1 (en) | 2006-07-14 |
IL170519A (en) | 2010-12-30 |
IL170519A0 (en) | 2006-10-05 |
EP1601352B1 (en) | 2008-01-23 |
WO2004080450A3 (en) | 2005-02-24 |
EP1457206A1 (en) | 2004-09-15 |
AU2004218938A1 (en) | 2004-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4746726B2 (ja) | フェノフィブレートとビタミンeの組成物およびその 治療上の用途 | |
RU2640561C2 (ru) | Повышение биодоступности лекарственных средств при терапии налтрексоном | |
JPH07507569A (ja) | ヒトの窒素保持の促進方法 | |
JP2000508659A (ja) | 心血管疾患関連の危険性を低減する組み合わせ療法 | |
US20030012827A1 (en) | Omega-3 fatty acids in the treatment of depression | |
AU758181B2 (en) | Therapeutic agents | |
JP4928256B2 (ja) | 肥満を治療するための、フィブラート系薬剤及びオルリスタットの使用 | |
ZA200103918B (en) | Combination of cerivastatin and fibrates. | |
CN1777417B (zh) | PPARα激动剂和二甲双胍降低血清甘油三酯的用途 | |
WO2001024792A9 (en) | Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog | |
US20020147206A1 (en) | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | |
US6890941B1 (en) | Compositions containing HMG Co-A reductase inhibitors and policosanol | |
KR20010051558A (ko) | 아포 b분비/mtp억제제의 용도 | |
CN106727480A (zh) | Fex-3在制备抗肥胖症药物中的应用 | |
ES2379165T3 (es) | Uso de un agonista de PPAR-alfa para tratar la ganancia de peso asociada con un tratamiento con un agonista de PPAR-Gamma | |
WO2021065661A1 (ja) | 筋肉量の低下抑制、低下予防、維持、回復又は増加用組成物 | |
RU2234917C2 (ru) | Терапевтические средства | |
JP2012036173A (ja) | 血管内皮障害改善剤 | |
US20050059741A1 (en) | Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-1 | |
CN104053440A (zh) | 用于预防或治疗高甘油三酯血症或高甘油三酯血症相关疾病的药物组合物 | |
EP1388351A1 (en) | Use of fibrate to treat weight gain associated with rosiglitazone treatment | |
KR20070102953A (ko) | 고지혈증의 예방 및/또는 치료를 위한 의약 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20060922 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070216 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20090702 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090702 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100615 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100913 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100921 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101013 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110209 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110307 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110729 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110930 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111226 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120124 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120210 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150217 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |